Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 10 Dec 2025
- Ended
- 14 Jan 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Suspected Sepsis Group - Diagnostic Measurements
- Control Group - Diagnostic Measurements
- Record updated
- 20 February 2026
- Why it stopped
- Could not get through IRB submission and co-investigators with needed skillsets for study departed organization
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Subjects 18 years old
- With clinical symptoms suggestive of sepsis Control Group
- age matched
- gender matched
- cardiovascular risk factor matched
Who cannot take part
- n/a
Where in United States
- University of Alabama at BirminghamBirmingham, United States
About the trial
What the trial wants to find out
This proposal hypothesizes that mitochondrial bioenergetics in the patient will correspond to mtDNA DAMPs levels and markers of inflammation. We predict these will serve as a prognostic indicator of Sepsis induced cardiac dysfunction (SICD) outcomes. Successful completion of these studies will provide a clearer understanding of the etiology of SICD development and therefore will have a high impact on biomedical research by identifying a new mechanism for understanding sepsis induced organ failure. Importantly, they will also provide a means for more directed and focused therapies, based upon individual bioenergetic/mitochondrial-mediated inflammation profiles. The combined, complementary expertise of the Mentor/co-primary investigators (Drs. Mathru and Ballinger) provide an excellent combination in both basic and translational research. They also have experience conducting studies and publications that will strengthen this research project. Importantly, the methods for characterizing mitochondrial bioenergetics from platelets were developed here at UAB, and methods for quantitative assessment of mtDNA DAMPs have been recently developed.
The 2 groups in the trial
- suspected sepsis group
We will perform a prospective observational study of patients admitted to the intensive care units (ICU) with suspected sepsis or septic shock.
Treatment: Suspected Sepsis Group - Diagnostic Measurements
- control group
This group will be compared to suspected sepsis or sepsis shock patients. The control group will be age matched, gender-matched, and cardiovascular risk-factor matched controls.
Treatment: Control Group - Diagnostic Measurements
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 20 February 2026